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Atrial fibrillation (AF) is the most common sustained arrhythmia encountered in clinical prac-
tice with growing prevalence in developed countries. Several medical and interventional
therapies, such as atrial specific drugs and pulmonary vein isolation, have demonstrated
prevention of recurrences. However, their suboptimal long-term success and significant
rate of secondary effects have led to intensive research in the last decade focused on
novel alternative and supplemental therapies. One such candidate is polyunsaturated fatty
acids (PUFAs). Because of their biological properties, safety, simplicity, and relatively cheap
cost, there is a special clinical interest in omega-3 PUFAs as a possible antiarrhythmic agent.
Obtained from diets rich in fish, they represent one of the current supplemental therapies.
At the cellular level, an increasing body of evidence has shown that n-3 PUFAs exert a
variety of effects on cardiac ion channels, membrane dynamic properties, inflammatory
cascade, and other targets related to AF prevention. In this article, we review the current
basic and clinical evidence pertinent to n-3 PUFAs in AF treatment and prevention. We also
discuss controversial outcomes among clinical studies and propose specific subsets of AF
patients who will benefit most from n-3 PUFAs.
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INTRODUCTION
Atrial Fibrillation (AF) is the most common sustained arrhythmia
encountered in clinical practice (Kannel et al., 1998). In developed
countries the arrhythmia is associated with doubling of mortality
in both sexes and is one of the main causes of embolism (Wolf et al.,
1991). Although AF already represents an important health care
problem, its prevalence is estimated to increase in the next decade
(Miyasaka et al., 2006). AF is classified by how long the patient has
had the arrhythmia. AF that lasts less than 7 days is classified as
paroxysmal. AF that lasts longer than 7 days, without a return to
sinus rhythm, is designated as persistent. Persistent AF lasting for
more than 1 year is termed long-standing AF as long as a rhythm
control strategy is still pursued. However, when the rhythm con-
trol is no longer pursued the arrhythmia is designated as per-
manent AF (Camm et al., 2010). Current therapeutic options,
either antiarrhythmic drugs (amiodarone, flecainide, vernakalant,
dronedarone, etc.) or radiofrequency catheter-based procedures
have limited efficacy and are not completely free of complica-
tions (Lafuente-Lafuente et al., 2006; Cappato et al., 2010). This
is because as the arrhythmia perpetuates there is substantial atrial
remodeling that promotes the maintenance of AF (Nattel et al.,
2008).
Therefore, as the prevalence of AF increases, preventing its first
episode or recurrences before it becomes permanent is a crucial
component of treatment. Currently, therapies aimed at prevent-
ing recurrences (Healey et al., 2005; Lafuente-Lafuente et al., 2006;
Singh et al., 2007) have not demonstrated an elimination of the
arrhythmia burden or a wide safety profile. While in the last decade
new multichannel profile and more atrial specific antiarrhythmic
drugs have been developed, they are still not without substan-
tial side effects and can be pro-arrhythmic (Kober et al., 2008).
Therefore, novel therapeutic options are needed to improved AF
management (Dobrev et al., 2012). An increasing amount of scien-
tific evidence has suggested fish oil dietary supplement as a simple,
safe, and relatively cheap adjunct to existing therapies (Mozaffar-
ian et al., 2004; Calo et al., 2005; Nodari et al., 2011). Here, we aim
to review the current knowledge regarding the role of polyunsat-
urated fatty acids (PUFAs) as a therapeutic used for the treatment
and prevention of AF. Using a bench to the bedside approach, we
will attempt to identify the appropriate AF candidates who will
successfully respond to PUFAs.
BIOCHEMISTRY OF POLYUNSATURATED FATTY ACIDS
Fatty acids are essential constituents of the cell membrane. Catego-
rized by the length of their chains they are classified as short (fewer
than 6 carbon atoms), medium (6–12 carbon atoms), or long
(greater than 12 carbon atoms). They are further classified as sat-
urated or unsaturated. Saturated fatty acids have no double bonds
between their carbon atoms allowing the molecule to become“sat-
urated” with the maximal number of possible hydrogen atoms
attaching. Unsaturated forms of fatty acids possess biophysical,
structural, and dynamic properties essential for normal cellular
function (Leaf et al., 2005). For Omega-3 (n-3 fatty acids), the
terminal double bond is on C3 counting from the methyl end
of the hydrocarbon chain. The more commonly encountered n-6
(or omega-6) PUFAs have the terminal double bond on C6. The
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long hydrocarbon chain of the n-3/n-6 PUFAs, with multiple dou-
ble bonds and with the first double bond occurring in the C3/C6
position result in complex and unique 3-dimensional configu-
rations of PUFAs that are essential to their biological properties
(Mozaffarian and Wu, 2011).
Fatty acids required for normal physiological functions that
are produced by the body but obtained from food are called essen-
tial. Two of these are linoleic (n-6 PUFA) and α-linolenic (n-3
PUFA) acids. Once ingested, biochemical pathways can further
metabolize essential fatty acids into long-chain more unsaturated
derivatives. Linoleic acid can be converted into arachidonic acid
and α-linolenic acid into eicosapentaenoic and docosahexaenoic
acids (EPA and DHA, respectively; Burdge et al., 2002). However,
endogenous conversion is very limited in humans (8% assum-
ing the best scenario), which makes tissue and circulating EPA
and DHA levels primarily dependent on direct dietary consump-
tion (Burdge, 2004). While plants are a good source of linoleic
and α-linolenic acids, longer chain n-3 fatty acids are mainly
obtained from fish (tuna, herring, mackerel, etc.). In humans,
fish oil supplements result in progressively higher proportions of
EPA, DHA, and total n-3 PUFAs in atrial phospholipids, along
with a reciprocal lowering of long-chain n-6 PUFAs, predomi-
nantly arachidonic acid (Metcalf et al., 2007). Animal and human
studies demonstrate a progressive incorporation of n-3 PUFAs
in the myocardial cell membrane over a 30-day period (Owen
et al., 2004; Metcalf et al., 2007). Certain factors such as age, dia-
betes, body mass index, etc. could affect the incorporation of n-3
PUFAs into the cell membrane (Sands et al., 2005). Therefore, the
slow and gradual incorporation of n-3 PUFAs into the membrane
phospholipids should be taken into consideration when assess-
ing the beneficial effects of PUFAs supplemental therapy, since a
delay in protection can be expected. This has been observed when
prevention of total mortality and sudden cardiac death was exam-
ined after the initiation of n-3 PUFA supplementation (Marchioli
et al., 2002). Similarly, diverging results on the rate of recur-
rences after a DC shock in patients with persistent AF may also
be partially explained by differences in the duration of n-3 PUFA
therapy before cardioversion (Bianconi et al., 2011; Nodari et al.,
2011).
CELLULAR EFFECTS OF POLYUNSATURATED FATTY ACIDS
A large body of evidence supports the role of n-3 PUFAs in sta-
bilizing the cardiomyocyte membrane and altering cardiac cells’
electrophysiology (Leaf et al., 2003). Interestingly, some exper-
iments have demonstrated that n-3 PUFAs exert their effects
without strong ionic or covalent binding to specific targets in
the cell membrane. It is currently accepted that their incorpora-
tion within the hydrophobic tail of the cardiomyocyte membrane
phospholipids is sufficient to elicit electrophysiological changes,
and even antiarrhythmic action (Kang and Leaf, 1994). However,
direct interaction with proteins of certain cardiac ion channels
such as Nav1.5 has also been suggested by introducing single amino
acid mutations in the wild type protein that significantly reduced
the expected potency of EPA to inhibit the fast sodium current
(I Na; Xiao et al., 2001).
The effects of PUFAs on cardiac ionic currents have been pro-
posed as a major player in protection against AF. Acute effects of
PUFAs on the biophysical properties of ion channels may substan-
tially differ from those of chronically administered PUFAs that are
gradually incorporated into the cell membrane (Den Ruijter et al.,
2007). In human atrial cells, EPA and DHA acutely inhibit I Na
by shifting the potential of I Na availability toward more negative
voltages and increasing I Na inactivation at resting states (Li et al.,
2009). This effect on I Na has also been observed in HEK 293 cells
expressing human cardiac sodium channels and in neonatal rats
(Xiao et al., 1995, 1998). In contrast with the acute effects, peak I Na
was unaffected by incorporated n-3 PUFAs in ventricular myocytes
isolated from pigs and rats fed with a diet rich in fish oil (Leifert
et al., 2000; Verkerk et al., 2006).
In addition to affecting I Na the antiarrhythmic properties of
PUFAs have also been attributed to their capability to modulate
the L-type calcium channel (I Ca-L; Xiao et al., 1997) and the human
ether-a-go-go-related gene (HERG) channel, which mediates the
repolarizing rapid delayed rectifier K+ current (I Kr; Guizy et al.,
2005). Similar to the effects described on I Na, no changes were
observed on I Kr density and calcium homeostasis (diastolic Ca2+
and Ca2+ transient amplitude) in pig ventricular myocytes with
incorporated sarcolemmal n-3 PUFAs (Verkerk et al., 2006). In the
same study and in line with the acute administration (Xiao et al.,
2004), chronic administration of n-3 PUFAs resulted in reduced
Na+-Ca2+ exchange current (I NCX). This reduction may explain
the decreased propensity to develop delayed after depolarizations
(Blaustein and Lederer, 1999). Moreover, changes in membrane
phospholipids have been observed in rat atrial myocytes after a
fish oil dietary supplement compared to saturated and monoun-
saturated diets. The fish oil dietary supplement was associated
with calcium sparks of smaller area, and shorter duration in
cells with a higher ratio of n-3 to n-6 PUFAs (Honen and Saint,
2002). This may contribute to prevent diastolic calcium release and
decrease the propensity of delayed after depolarizations, which can
initiate AF.
With regards to the other repolarizing potassium currents, in
human atrial cells, EPA and DHA significantly inhibit the ultra-
rapid delayed rectifier K+ current (I kur) and the transient outward
K+ current (I to; Li et al., 2009). The inhibition of I kur is of spe-
cial interest since represents an atrial specific current (Li et al.,
1996), and its blockade might lead to AF termination (Blaauw
et al., 2004). Although attractive, specific I kur-blockade may not
be effective to terminate persistent AF and certain AF models, in
which I Kur is decreased and increased inward rectifier K+ currents
may counterbalance the potential effect of blocking I Kur in action
potential duration (Van Wagoner et al., 1997; Pandit et al., 2011).
Chronic treatment with EPA at low concentrations (1µM) may
increase I Kur current. Conversely higher concentrations of DHA
and EPA (30µM; more physiological) decrease the expression of
Kv1.5 protein channel (principal molecular component of I Kur;
Koshida et al., 2009).
In human atrial cells, no significant effects have been recorded
in the main inward rectifier potassium current (I K1) after expos-
ing the cells to oleic acid (Crumb et al., 1999). The same results
were obtained in ferret cardiomyocytes after acute administration
of n-3 PUFAs (Xiao et al., 2002). Conversely, incorporation of
n-3 PUFAs into the sarcolemma results in I K1 increase by ≈50%,
which shortens the action potential duration, reduces delayed after
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depolarizations and triggered activity (Verkerk et al., 2006; Den
Ruijter et al., 2008). The slow delayed rectifier K+ current (I Ks)
also shows significant increase after incorporation of n-3 PUFAs
in the sarcolemma of ventricular myocytes (Verkerk et al., 2006).
Acute effects on I Ks differ depending on the type of n-3 PUFA.
While DHA has shown to increase I Ks magnitude, EPA does not
exert any significant effect on I Ks (Doolan et al., 2002).
Unsaturated free fatty acids such as oleic, linoleic, and arachi-
donic acids reversibly inhibited the ATP-dependent gating of
native acetylcholine-sensitive K+ current (I K-Ach) in rat atrial cells
(Kim and Pleumsamran, 2000). Free unsaturated fatty acids of the
cardiac cell membrane seem to be crucial to keep the I K-ACh chan-
nel in the short-lived, single open state, and maintain low channel
activity despite the presence of ATP in the cell. The role of I K,Ach
in AF is well described in experimental models of AF. Activation
of these channels causes hyperpolarization of the resting mem-
brane potential and shortening of the action potential duration.
Heterogeneous distribution of I K,ACh channels in the atria gen-
erate non-uniform distribution of refractory periods and make
the atria prompt to AF (Moe and Abildskov, 1959; Sarmast et al.,
2003).
In addition, n-3 PUFAs might affect stretch activated channels
(SAC),which are non-specific ion channels activated in response to
mechanical deformation of the membrane. In rat atrial myocytes,
membrane compliance increases after acute addition of the n-
3 PUFAs DHA and EPA (Jahangiri et al., 2000). Langendorff-
perfused hearts of rabbits on a dietary fish oil supplement were
more resistant to stretch-induced AF compared to hearts from
controls (Ninio et al., 2005). This is similar to the results of ear-
lier experiments (Bode et al., 2001) after blocking SAC by the
tarantula venom peptide GsMtx-4. Consequently, it could be spec-
ulated that an increase in membrane fluidity could protect against
stretch-induced vulnerability to AF. However, it remains unknown
whether PUFAs modify the biophysical properties of SAC.
Polyunsaturated fatty acids may also act through alternative
mechanisms derived from their effects on inflammation, endothe-
lial function, atherosclerosis, etc. Through the activation of tran-
scription factors such as peroxisome proliferator-activated recep-
tors (PPARs) and nuclear factor kappa B (NFκB), n-3 PUFAs are
able to regulate metabolism and other cell and tissue responses,
such as inflammation. Healthy human volunteers who undertook
a dietary fish oil supplement showed decreased production of
tumor necrosis factor-α (TNFα), interleukine-1β (IL-1β), IL-6,
and various growth factors by monocytes or mononuclear cells
that were stimulated with bacterial endotoxin (Endres et al., 1989;
Trebble et al., 2003). Changes in cell membrane composition after
n-3 PUFA supplementation alter the production and potency
of eicosanoid and eicosanoid-like mediators produced from the
n-6 PUFA arachidonic acid (prostaglandins, thromboxanes, and
leukotrienes). These have well-established roles in the regulation
of inflammation and immunity (Calder, 2006).
Therefore, based on acute effects and incorporation of n-3
PUFAs into the cardiac cell membrane, PUFAs may decrease atrial
heterogeneity and Ca+2-induced triggered activity, both leading to
lower risk of AF onset and recurrences. Altogether, cellular studies
suggest that long-term n-3 PUFAs supplementation may act as an
upstream therapy for substrate modification and membrane sta-
bilization rather than a pure antiarrhythmic agent. Summarized
acute and chronic n-3 PUFAs effects on cardiac ion currents are
shown in Table 1.
Table 1 | Acute vs. chronic n-3 PUFAs effects or cardiac ion currents.
Author/sYear Ion Current PUFAs Effects Cell type
Acute Chronic
Li et al. (2009); Xiao et al. (1995, 1998) INa Decrease Human atria, HEK 293, neonatal rat ventricular myocytes
Leifert et al. (2000); Verkerk et al. (2006) Unaffected Pig and rat ventricular myocytes
Li et al. (2009) IKur Decrease Human atria
Koshida et al. (2009) Decrease
(30µM)
Transfected green monkey kidney fibroblast cells and rat
atrium
Li et al. (2009) I to Decrease Unknown Human atria
Xiao et al. (1997) ICa-L Decrease Rat ventricular myocytes
Verkerk et al. (2006) Decrease Pig ventricular myocytes
Xiao et al. (2004) INCX Decrease HEK 293t
Verkerk et al. (2006) Decrease Pig ventricular myocytes
Guizy et al. (2005) IKr Decrease Chinese hamster ovary cells expressing HERG
Verkerk et al. (2006) Unaffected Pig ventricular myocytes
Doolan et al. (2002) IKs Increase (DHA) KvLQTl and hminK injected in Xenopus oocytes
Verkerk et al. (2006) Increase Pig ventricular myocytes
Xiao et al. (2002) IKI Unaffected Adult ferret cardiomyocytes
Verkerk et al. (2006) Increase Pig ventricular myocytes
Kim and Pleumsamran (2000) IK-ACh Decrease Unknown Rat atrium
SAC Unknown Unknown
SAC, stretch activated channels; DHA, docosahexaenoic acid.
www.frontiersin.org September 2012 | Volume 3 | Article 370 | 3
Salvador-Montañés et al. Omega-3 PUFAs in atrial fibrillation
EFFECTS OF POLYUNSATURATED FATTY ACIDS IN
EXPERIMENTAL MODELS OF AF
Experimental models of AF show much less variability than human
populations at large. This allows the identification of specific
mechanisms or substrates suitable for potential treatment with
PUFAs. Models mainly based on electrical remodeling, structural
remodeling, or inflammatory-related models can provide valuable
insights to understand the role of n-3 PUFAs in clinical AF.
Oral supplementation with n-3 PUFAs (DHA and EPA acids),
commencing 2 weeks before tachypacing onset and continuing
through the fast pacing period (7 days), did not significantly affect
AF duration and atrial refractory period compared to sham-
operated controls in a dog model of AF where the ventricular rate
was controlled by atrioventricular block and ventricular demand
pacing. Further, dogs that underwent ventricular tachypacing with
the same regimen of n-3 PUFA supplementation showed decreased
congestive heart failure-related atrial fibrosis and attenuated AF
promotion induced by ventricular tachypacing (Sakabe et al.,
2007). The authors found significantly decreased expression of
phosphorylated mitogen-activated protein (MAP) kinases, which
are particularly important in causing tissue fibrosis in both heart
failure animals and AF patients (Goette et al., 2000; Petrich and
Wang, 2004). In a dog model of AF with simultaneous fast atrial
and ventricular pacing, n-3 PUFA supplementation resulted in less
conduction time heterogeneity in the left atrium, and prevented
pacing-induced increase in collagen turnover and collagen deposi-
tion in atrial appendages. PUFAs reduced both AF inducibility and
duration of inducible AF (Laurent et al., 2008). Echocardiographic
assessment of mechanical remodeling in those animals showed a
similar decrease in left atrial-emptying function in treated animals
and controls (Laurent et al., 2008).
However, there are discrepancies about the effects of PUFAs in
the literature that appear to be model dependent. For example,
acute administration of PUFAs prevented atrial electrical remod-
eling by significantly reducing the shortening of atrial effective
refractory period caused by several hours of fast atrial pacing in
dogs (Da Cunha et al., 2007). This acute effect was not observed
in the same animal model of PUFAs treatment under long-term
fast atrial pacing (Sakabe et al., 2007). Interestingly, both dietary
supplements and acute administration of n-3 PUFAs prevented
vagally induced AF in dogs (Sarrazin et al., 2007). Experimen-
tal results in vagally induced AF correlate with the relevant role
of PUFAs in the cardiac cell membrane to modulate I K,ACh as
described above.
The antiarrhythmic effects of PUFAs have been observed in
non-tachypaced models of AF as well. Accumulating evidence
indicates that inflammatory pathways are of significance in AF.
Although some evidence suggests that inflammation might be a
causative agent for AF (Sata et al., 2004), a substantial body of evi-
dence supports that AF and inflammatory pathways have a bidirec-
tional relationship (Friedrichs et al., 2011). After cardiac surgery,
leukocytosis and pro-inflammatory cytokines have been directly
related to the incidence of post-operative AF. As the cytokines
raise, the risk of post-operative AF concomitantly increases (Ishida
et al., 2006). n-3 PUFAs show anti-inflammatory effects that may
prevent AF episodes related to a highly inflammatory environ-
ment. Experimentally, in a canine model of open-chest sterile
pericarditis, oral PUFAs supplement for 4 weeks before the oper-
ation and 2 days afterward resulted in less AF inducibility and
maintenance than in a control group under regular feeding. Before
the operation, there were no significant differences in conduc-
tion time, atrial effective refractory period (AERP; defined as the
longest S1–S2 coupling interval that fails to depolarize the atria)
and inflammatory markers between PUFAs group and controls.
Two days after surgery, C-reactive protein (CRP), IL-6, and TNF-α
levels were significantly lower in the PUFAs group. PUFAs supple-
mentation also resulted in longer AERP and shorter intra-atrial
conduction time after surgery (Zhang et al., 2011).
MECHANISMS UNDERLYING AF AND THEIR LINK TO
CELLULAR AND EXPERIMENTAL PUFAs EFFECTS
Although the mechanisms underlying AF are not completely
understood, the arrhythmia is believed to be reentrant. There
is increasing evidence supporting the role of a unique or small
number of functional reentrant sources (rotors) maintaining the
arrhythmia (David Filgueiras Rama and José Jalife, 2011). This is
largely because of the elucidation of the molecular mechanisms
of reentry. Theoretically, it has been known that shortening of
the action potential duration and increasing excitability can facil-
itate reentry (Pandit et al., 2005). However, it was not until the
last decade that the role of inward rectifier K+ currents, such as
I K,ACh or I K1, and their ability to increase reentrant frequency
and facilitate AF became a well-established molecular mechanism
responsible for AF. For a complete review on the role of inward
rectifiers (see Ehrlich, 2008; Jalife, 2011). While I K,ACh may have a
preferential role in paroxysmal AF and explain left-to-right differ-
ences in rates of activation (Voigt et al., 2010), the current seems
to decrease in persistent AF. However, ionic remodeling leads to
an increase in I K1 and constitutive active I K,ACh (Dobrev et al.,
2001, 2005; Makary et al., 2011). Conversely, as AF becomes per-
sistent extensive data show decrease in I to, I Kur, I Na, and the L-type
Ca+2 current (Van Wagoner et al., 1997, 1999; Dobrev et al., 2001;
Sossalla et al., 2010).
While reentry seems to perpetuate the arrhythmia, Ca2+-
dependent triggered activity may initiate AF. While the sponta-
neous release of Ca+2 and triggered activity implicate abnormal
sarcoplasmic reticulum (SR) Ca+2 release as a trigger, the fre-
quency of triggered activity, and spontaneous Ca+2 release are
much slower than the typical AF activation rate (<1 vs. 6–9 Hz,
respectively;Atienza et al., 2006,2009;Voigt et al., 2012). As a result,
it is unlikely they are the mechanism maintaining the arrhythmia.
This idea is further supported by AF models like stretch-induced
AF, in which a more depolarized resting membrane potential and
the activation of SAC enable the generation of triggered activity.
Even in the presence of a high rate of focal activity reentry was
required to sustain AF (Filgueiras-Rama et al., 2012).
However, it is important to note that as the arrhythmia per-
sists, electrical remodeling and functional changes in subcellular
structures lead to higher susceptibility to Ca2+-dependent trig-
gered activity. Ryanodine (RyR2) dysfunction and SR Ca2+ leak
may contribute to further paroxysms and persistence of AF. Under
certain conditions of excitability, anatomic and functional obsta-
cles may interfere with propagation of regular or Ca2+ dependent
waves, which may cause the formation of self-sustained vortices.
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Concomitantly, larger inward Na+-Ca2+-exchange current (I NCX)
for a given SR Ca2+ release further increase the likelihood of
delayed after depolarizations and triggered activity (Voigt et al.,
2012).
In addition to electrical remodeling, structural changes can
facilitate the long-term maintenance of AF (Nattel et al., 2008).
Structural changes include atrial dilatation and an increase in
atrial fibrosis. This is a consistent finding in AF models asso-
ciated with congestive heart failure (Morillo et al., 1995; Li
et al., 1999). Extracellular matrix dysregulation and atrial fibrosis
increases atrial conduction heterogeneity and plays an impor-
tant role in stabilizing reentry and making larger areas of the
atria suitable for harboring reentry. Different inter related sig-
naling pathways appear to be involved in the development of
atrial fibrosis. The most prominent pathways studied are the
renin-angiotensin system (RAS), transforming growth factor-β1
(TGF-β1), and the inflammation/oxidative stress pathways (Lin
and Pan, 2008). Furthermore, elevated inflammatory mediators
varied according to the different sub-types of the arrhythmia.
There is a graded increase in N-terminal pro-brain natriuretic
peptide (NTpBNP) and TNF-α with the duration and type of AF
(permanent> persistent> paroxysmal). Patients with lone AF (no
overt structural heart disease) are less likely to have elevated con-
centrations of biomarkers (IL-10, TNF-α, and NTpBNP; Li et al.,
2010). Baseline levels of biomarkers and further decrease after car-
dioversion may also be used to predict sinus rhythm maintenance
during the following year in patients with lone AF (Leftherio-
tis et al., 2009). However, structural remodeling does not occur
in all AF models. Predominant electrical remodeling with min-
imal or no changes in atrial fibrosis are present in tachypacing
induced AF models even after long periods of fast pacing, as long
as tachycardiomyopathy is not present (Ausma et al., 1997).
Synthesizing all this together, the role of n-3 PUFAs in terminat-
ing AF by modulation of cardiac ion channels seems unlikely based
on the limited effects observed with chronic PUFAs supplements.
Moreover, once AF is initiated, the increase in I K1 after PUFAs
supplement may facilitate reentry (Verkerk et al., 2006). However,
n-3 PUFAs have also been shown to prevent AF, and it is speculated
that an increase in membrane fluidity and I K1 may protect against
stretch-induced triggered activity and AF initiation. Similarly, a
decrease in abnormal Ca+2 release may also prevent focal trig-
gered activity initiating AF (Honen and Saint, 2002). The crucial
role of PUFAs to control ATP-induced increase in KACh channel
activity may also be important in persistent AF, in which I K,ACh
is constitutively active. Additionally, it has been proposed that the
PUFAs antiarrhythmic effects lie in the ability of n-3 PUFAs to
modify the atrial substrate that perpetuates the arrhythmia. Thus,
PUFAs have the capability to attenuate the inflammatory cascade
and adverse remodeling occurring in response to mechanical stress
(Sakabe et al., 2007; Laurent et al., 2008).
CLINICAL IMPLICATIONS OF PUFAs IN AF POPULATION
The AF population represents a large source of variability. There-
fore, specific AF subsets could benefit more than others from using
n-3 PUFA dietary supplementation. It is not surprising there are
different responses to PUFAs depending on the type of AF (lone,
paroxysmal, persistent, and permanent). Further, the evaluation
of the efficacy of PUFAs is convoluted by concomitant therapies,
degree of inflammatory biomarkers, and time-course of the sup-
plementary dietary therapy before outcomes analysis. Based on the
experimental studies we have discussed so far, we speculate that
PUFAs are not predominantly antiarrhythmic ion channel block-
ers. Rather, they play an important role to prevent AF onset in
disease states with strong inflammatory and structural remodeling
components. Results from different trials highlight the poten-
tial role of n-3 PUFAs in preventing AF onset and recurrences
mainly from persistent AF populations, which supports their role
as upstream therapy.
The study by Calo et al. (2005) in patients who underwent
coronary artery bypass graft (CABG) surgery showed that n-3
PUFA supplementation (EPA/DHA ratio 1:2) at least 5 days before
surgery reduced the incidence of post-operative AF by≈50%. Fur-
ther, it was associated with a shorter hospital stay (Calo et al.,
2005). Similar results were observed in a randomized trial with
the same type of surgery and same PUFAs regimen (Sorice et al.,
2011). Conversely, another randomized clinical trial in patients
who underwent CABG surgery did not show statistical differences
between n-3 PUFAs and placebo groups (Saravanan et al., 2010).
This discrepancy may be explained by different designs of the stud-
ies. The EPA/DHA supplementation ratio was 1:2 in Calò’s study
and 1.2:1 in the study by Saravanan et al. (2010). Considering that
DHA may have greater impact on AF prevention (Virtanen et al.,
2009), the results may be somehow affected by the study design.
It also should be noted that Calò’s study included AF episodes
lasting>5 min compared to>30 s in Saravanan’s. This resulted in
a much higher AF incidence, without a clear clinical significance
of such short episodes. Finally, the use of concomitant β-blockers
and statins was much lower in the study by Calò (85 and 98%
compared with 57 and 56%). Optimization of these agents could
have decreased the beneficial effects of n-3 PUFAs.
Two other randomized trials in patients who underwent cardiac
surgery either CABG and/or valvular replacement did not show
any beneficial effect of n-3 PUFAs (EPA/DHA ratio 1.2/1.4:1) in
preventing post-operative AF compared to controls (Heidarsdottir
et al., 2010; Farquharson et al., 2011). The study by Heidarsdot-
tir et al. (2010) was carried out in an Icelandic population with
approximately 80% of participants taking cod liver oil or other
fish oils, which resulted in very small changes of plasma n-3 PUFAs
concentrations after the regimen. In the second study by Farquhar-
son et al. (2011) the results showed a trend to toward a decrease in
incidence of AF in the n-3 PUFAs group. However the sample size
was underestimated for the AF rates observed in the study, which
resulted in no statistically significant differences. The discussed
clinical studies evaluating new-onset AF following cardiac surgery
are summarized in Table 2.
Beyond post-operative AF, over a 12-year follow-up period
regular consumption of n-3 PUFAs (tuna and other broiled or
baked fish ≥5 times per week) showed ≈30% lower incidence
of AF among subjects older than 65 years after adjustment for
other risk factors (Mozaffarian et al., 2004). Although those obser-
vational results were encouraging, subsequent randomized trials
brought up controversial results. The study by Nodari et al. (2011),
in patients with persistent AF and at least one relapse after car-
dioversion, showed significant decrease in AF recurrences after
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Table 2 | Clinical trials in new-onset AF following cardiac surgery.
Author
year
Age
(years)
Design Study
population
PUFAs dosage No of
patients
Duration Results
Calo et al.
(2005)
65.6±8.5 Open label/
randomized
Pre/post-CABG, SR EPA/DHA 1:2 160 At least 5 days before
CBAG until discharge
Reduced post-CABG surgical
AF and shorter hospitalization
Saravanan
et al. (2010)
66 (58–73) Double blind/
randomized
Pre/post-CABG, SR EPA/DHA 1.2:1 108 At least 5 days before
CBAG until
discharge/5 days
No reduction in AF after
CABG surgery
Heidarsdottir
et al. (2010)
67 (43–82) Double blind/
randomized
Pre/post-cardiac
surgery, SR
EPA/DHA 1.2:1 168 5–7 days before CABG
and/or valvular repair until
discharge/14 days
No reduction in AF after
cardiac surgery
Farquharson
et al. (2011)
64±11 Double blind/
randomized
Pre/post-cardiac
surgery, SR
EPA/DHA 1.4:1 194 3 weeks before CABG
and/or valve replacement
until discharge/6 days
Trend to decrease in
post-surgical AF. Decreased
length of stay in the lCU
Sorice et al.
(2011)
63±10 Open label/
randomized
Pre/post-cardiac
surgery, SR
EPA/DHA 1:2 201 At least 5 days before
CBAG until discharge
Decrease in “on-pump”
CABG surgical AF
AF, atrial fibrillation; CABG, coronary artery bypass graft surgery; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; ICU, intensive care unit; PUFA, omega-3
polyunsaturated fatty acids; SR, sinus rhythm.
Table 3 | Main clinical trials in non-postoperative AF onset and recurrent AF.
Author
year
Age
(years)
Design Study
population
PUFAs
Dosage
No of
patients
Duration Results
Mozaffarian
et al. (2004)
72(65–100) Observational
prospective
Population-based Tuna, baked
fish
4815 12 years Lower incidence of AF with fish
intake ≥1 time per week
Virtanen et al.
(2009)
52.8±5.3 Observational
prospective
Population-based men.
SR
Fish intake 2174 17.7 years High serum levels of n-3 PUFAs
decrease hospital diagnosis of AF
Kowey et al.
(2010)
60.5±12.8 Double blind/
Randomized
Symptomatic
paroxysmal/persistent
AF, SR
EPA/DHA
1.2:1
663 24 weeks
after
enrollment
No reduction in recurrent AF
Nodari et al.
(2011)
69.5±7 Double blind/
Randomized
Recurrent persistent
AF >1 month+ACE-
Is+Amiodarone
EPA/DHA
1.2:1
199 1 year Decrease in persistent AF
recurrences post-cardioversion
Bianconi
et al. (2011)
69.2±7.9 Double blind/
Randomized
Persistent AF >1 month.
Mainly “lone AF”
EPA/DHA
1.2:1
204 6 months after
enrollment
No reduction in persistent AF
recurrences post-cardioversion
Kumar et al.
(2012)
61±13 Open label/
Randomized
Persistent AF
>1 month±ACE-
Is/Amiodarone/Sotalol
EPA/DHA1.3:1 178 1 year Decrease in persistent AF
recurrences post-cardioversion
ACE-Is, angiotensin-converting enzyme inhibitors; AF, atrial fibrillation; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; PUFA, omega-3 polyunsaturated fatty
acids; SR, sinus rhythm.
cardioversion and n-3 PUFA supplementation (EPA/DHA ratio
1.2:2). More recently, in a similar AF population, the study by
Kumar et al. (2012) showed that fish oil supplementation resulted
in a sixfold prolongation in the median time to AF recurrence
compared to controls. Conversely, two other randomized trials
by Kowey et al. (2010); Bianconi et al. (2011) did not show
any beneficial effect of n-3 PUFAs in preventing AF recurrences
in persistent AF patients after cardioversion or in sinus rhythm
patients with previously documented AF, respectively. Again, sev-
eral methodological factors may partly explain these discordant
findings. Nodari’s and Kumar’s studies included patients taking n-
3 PUFA supplementation for at least 4 weeks before cardioversion,
with a history of at least one previous cardioversion. Nodari’s
series also enrolled a population with high prevalence (≈90%) of
structural heart disease. Most patients in Bianconi’s study (≈60%)
were experiencing their first episode of AF and only 25% of
patients had a previous cardioversion. In addition, before car-
dioversion, the length of n-3 PUFAs therapy was shorter than the
time required for incorporation of PUFAs in the cell membrane
(≈28 days). This may explain why the majority of recurrences
occurred very early in follow-up (2–3 weeks), before the expected
biological effects of n-3 PUFAs. In addition, in both studies with
negative results the presence of structural heart disease was signif-
icantly lower than in Nodari’s study, which may represent a key
factor in understanding the potential role of PUFAs in prevent-
ing structural changes preferentially in patients with significant
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structural heart disease, similarly to the additional clinical bene-
fits of spironolactone therapy in patients with AF and structural
heart disease (Williams et al., 2011). The clinical studies evaluating
AF incidence and recurrences are summarized in Table 3.
FUTURE DIRECTIONS
Data from animal studies seem to support the role of n-3 PUFAs
as a therapeutic option in AF. AF models with intense structural
remodeling due to heart failure and ventricular tachypacing, post
open-chest surgery, and vagally induced AF have shown to benefit
from n-3 PUFA supplementation. These effects are also supported
by some of the effects of n-3 PUFAs at the cellular level. However,
more mechanistic insights are necessary to further understand the
specific pathways that make n-3 PUFAs an effective adjunctive
therapy to prevent AF. Arguably, this is because structural remod-
eling of the atria and acute inflammation may affect AF suscepti-
bility in a different manner based on the inflammatory pathways
involved. In fact, recent data have shown that some of those inflam-
matory markers affect the activity of certain cardiac ion channels,
as well as the interaction between cardiomyocytes and fibroblasts
(Ottaviano and Yee, 2011; Ramos-Mondragon et al., 2011). As a
result new experimental data is needed to understand how n-3
PUFAs influence the release of inflammatory markers and how
those markers influence AF.
Changes in lipid composition of the sarcolemma seem to
modulate some cardiac ion currents such as I K,ACh and at least
indirectly affect membrane susceptibility to stretch (Kim and
Pleumsamran, 2000; Ninio et al., 2005). Specific changes in n-
3 PUFAs composition in the lipid membrane of cardiomyocytes
after dietary supplementation are currently unknown and need to
be addressed. It is also necessary to study the specific n-3 PUFAs
effects on SAC beyond the increase in membrane compliance.
Finally, DHA and EPA seem to exert different effects at the cellu-
lar level and clinical outcomes (Virtanen et al., 2009). New clinical
trials based on mechanistic effects described in experimental stud-
ies will be necessary to avoid confounding factors that appear to
be present in the current clinical trials.
CONCLUSION
Biochemical and biophysical properties of n-3 PUFAs give rise to
a variety of effects at the cellular and organ levels. They include
increasing cardiomyocyte membrane stability, modulation of the
biophysical properties of ion channels/cellular substructures, and
significant effects on the inflammatory/fibrosis signaling path-
ways. In light of experimental and clinical studies, the latter may
be especially important in preventing AF (post-operative or clin-
ical recurrences). Consequently, dietary supplementation of n-3
PUFAs may be considerably more beneficial in patients with pro-
nounced structural heart disease and atrial remodeling, high levels
of inflammatory biomarkers, and low baseline levels of circulating
PUFAs. New ongoing clinical trials, mainly focus on AF recur-
rences and post-operative AF, will hopefully help to pinpoint the
specific subset of AF population that will benefit most from n-3
PUFA supplementation.
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